In a study dedicated to the European pharmaceutical sector, the London establishment notes that the action posted performances broadly in line with those of the sector in 2021, despite better than expected results.
As a result, the discount of more than 20% that the title displays today seems to him totally unjustified.
“Sanofi will undoubtedly deliver impressive growth forecasts for 2022 and its growth potential should help make up for the 20% discount that the title shows in terms of PER 2022 compared to the sector”, forecast its analysts.
Liberum adds that the absence of threats from generic drugs combined with the growth prospects of Dupixent (atopic dermatitis) complete a medium-term picture deemed attractive.
The independent bank – which makes Sanofi its ‘top pick’ (preferred value) within the sector this year – adds that the laboratory should also benefit from clinical data on projects at the end of development.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held liable directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.